Literature DB >> 21120095

Clinical treatment of obsessive compulsive disorder.

Christopher Pittenger, Ben Kelmendi, Michael Bloch, John H Krystal, Vladimir Coric.   

Abstract

Obsessive compulsive disorder (OCD) was once thought to be extremely rare, but recent epidemiological studies have shown it to be the fourth most common psychiatric disorder (after substance abuse, specific phobias, and major depression). OCD is often a chronic disorder that produces significant morbidity when not properly diagnosed and treated. The mainstay of treatment includes cognitive behavioral therapy and medication management. The use of clomipramine in the 1960s and then the introduction of serotonin reuptake inhibitors in the 1980s represented important advances in the pharmacologic treatment of OCD. Despite effective treatment modalities, many patients demonstrate only a partial response or are resistant to available medications. SRI-resistant OCD is one of the few diagnoses in modern psychiatry for which invasive neurosurgical procedures remain part of the established treatment armamentarium. We review current treatment strategies used in the management of OCD symptoms.

Entities:  

Year:  2005        PMID: 21120095      PMCID: PMC2993523     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  82 in total

1.  Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.

Authors:  M A Crocq; Ph Leclercq; M S Guillon; P E Bailey
Journal:  Eur Psychiatry       Date:  2002-09       Impact factor: 5.361

2.  Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.

Authors:  D J Stein; C Bouwer; S Hawkridge; R A Emsley
Journal:  J Clin Psychiatry       Date:  1997-03       Impact factor: 4.384

3.  Clinical predictors of drug response in obsessive-compulsive disorder.

Authors:  S Erzegovesi; M C Cavallini; P Cavedini; G Diaferia; M Locatelli; L Bellodi
Journal:  J Clin Psychopharmacol       Date:  2001-10       Impact factor: 3.153

4.  Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.

Authors:  M Atmaca; M Kuloglu; E Tezcan; O Gecici
Journal:  Int Clin Psychopharmacol       Date:  2002-05       Impact factor: 1.659

5.  Regional 133xenon cerebral blood flow and cerebral 99mTc-HMPAO uptake in patients with obsessive-compulsive disorder before and during treatment.

Authors:  R T Rubin; J Ananth; J Villanueva-Meyer; P G Trajmar; I Mena
Journal:  Biol Psychiatry       Date:  1995-10-01       Impact factor: 13.382

6.  Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.

Authors:  Stefano Pallanti; Leonardo Quercioli; Matteo Bruscoli
Journal:  J Clin Psychiatry       Date:  2004-10       Impact factor: 4.384

7.  A family study of obsessive-compulsive disorder.

Authors:  D L Pauls; J P Alsobrook; W Goodman; S Rasmussen; J F Leckman
Journal:  Am J Psychiatry       Date:  1995-01       Impact factor: 18.112

8.  Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder.

Authors:  Elizabeth A Hembree; David S Riggs; Michael J Kozak; Martin E Franklin; Edna B Foa
Journal:  CNS Spectr       Date:  2003-05       Impact factor: 3.790

9.  Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Authors:  Eric Hollander; Nicolò Baldini Rossi; Erica Sood; Stefano Pallanti
Journal:  Int J Neuropsychopharmacol       Date:  2003-12       Impact factor: 5.176

10.  Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.

Authors:  T R Insel; D L Murphy; R M Cohen; I Alterman; C Kilts; M Linnoila
Journal:  Arch Gen Psychiatry       Date:  1983-06
View more
  8 in total

Review 1.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

2.  Attenuation of compulsive-like behavior by fluvoxamine in a non-induced mouse model of obsessive-compulsive disorder.

Authors:  Swarup Mitra; Abel Bult-Ito
Journal:  Behav Pharmacol       Date:  2018-06       Impact factor: 2.293

3.  Obsessive-compulsive symptoms and negative affect during tobacco withdrawal in a non-clinical sample of African American smokers.

Authors:  Mariel S Bello; Raina D Pang; Gregory S Chasson; Lara A Ray; Adam M Leventhal
Journal:  J Anxiety Disord       Date:  2016-10-05

Review 4.  Searching for host immune-microbiome mechanisms in obsessive-compulsive disorder: A narrative literature review and future directions.

Authors:  Emily A Troyer; Jordan N Kohn; Gertrude Ecklu-Mensah; Gajender Aleti; David R Rosenberg; Suzi Hong
Journal:  Neurosci Biobehav Rev       Date:  2021-02-24       Impact factor: 9.052

5.  Attenuation of Compulsive-Like Behavior Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Non-Induced Compulsive-Like Mice.

Authors:  Swarup Mitra; Mckenzie Mucha; Shailesh N Khatri; Richard Glenon; Marvin K Schulte; Abel Bult-Ito
Journal:  Front Behav Neurosci       Date:  2017-01-05       Impact factor: 3.558

6.  Transcriptome alterations are enriched for synapse-associated genes in the striatum of subjects with obsessive-compulsive disorder.

Authors:  Sean C Piantadosi; Lora L McClain; Lambertus Klei; Jiebiao Wang; Brittany L Chamberlain; Sara A Springer; David A Lewis; Bernie Devlin; Susanne E Ahmari
Journal:  Transl Psychiatry       Date:  2021-03-15       Impact factor: 6.222

7.  Deep brain stimulation for refractory obsessive-compulsive disorder: A review and analysis of the FDA MAUDE database.

Authors:  Mokshal H Porwal; Hamsitha Karra; Umesh Sharma; Danish Bhatti
Journal:  Surg Neurol Int       Date:  2022-09-02

8.  Obsessive-Compulsive Disorder in a 19-Year-Old Female Adolescent With Turner Syndrome.

Authors:  Surinder S Moonga; Aaron Pinkhasov; Deepan Singh
Journal:  J Clin Med Res       Date:  2017-11-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.